Get started
BASILEA PHARMACEUBASILEA PHARMACEUBASILEA PHARMACEU

BASILEA PHARMACEU

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

PK5 chart

Upcoming earnings

Next report date
Report period
H1 2024
EPS estimate
0.94CHF
Revenue estimate
‪86.00 M‬CHF

Key stats

Market capitalization
‪485.12 M‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
78.271
Basic EPS (TTM)
0.876CHF
Net income (FY)
‪10.45 M‬CHF
Revenue (FY)
‪157.63 M‬CHF
Shares float
‪11.00 M‬
Beta (1Y)
0.60

About BASILEA PHARMACEU

Sector
Health Technology
CEO
David Veitch
Headquarters
Allschwil
Website
basilea.com
Employees (FY)
147
Founded
2000
ISIN
CH0011432447
FIGI
BBG006M6Z321
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PK5 is 40.662 CHF — it has decreased by 1.65% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BASILEA PHARMACEU stocks are traded under the ticker PK5.
BASILEA PHARMACEU is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
PK5 stock is 1.81% volatile and has beta coefficient of 0.60. Check out the list of the most volatile stocks — is BASILEA PHARMACEU there?
PK5 earnings for the last quarter are 2.42 CHF per share, whereas the estimation was 0.81 CHF resulting in a 200.62% surprise. The estimated earnings for the next quarter are −2.01 CHF per share. See more details about BASILEA PHARMACEU earnings.
BASILEA PHARMACEU revenue for the last quarter amounts to ‪84.90 M‬ CHF despite the estimated figure of ‪64.73 M‬ CHF. In the next quarter revenue is expected to reach ‪71.93 M‬ CHF.
Yes, you can track BASILEA PHARMACEU financials in yearly and quarterly reports right on TradingView.
PK5 stock has fallen by 3.53% compared to the previous week, the month change is a 11.99% rise, over the last year BASILEA PHARMACEU has showed a 5.40% decrease.
PK5 net income for the last quarter is ‪−21.39 M‬ CHF, while the quarter before that showed ‪31.84 M‬ CHF of net income which accounts for −167.18% change. Track more BASILEA PHARMACEU financial stats to get the full picture.
Today BASILEA PHARMACEU has the market capitalization of ‪483.13 M‬, it has decreased by 0.49% over the last week.
No, PK5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PK5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BASILEA PHARMACEU stock right from TradingView charts — choose your broker and connect to your account.
PK5 reached its all-time high on Jan 24, 2023 with the price of 54.000 CHF, and its all-time low was 32.596 CHF and was reached on May 23, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 26, 2024, the company has 147.00 employees. See our rating of the largest employees — is BASILEA PHARMACEU on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BASILEA PHARMACEU technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BASILEA PHARMACEU stock shows the buy signal. See more of BASILEA PHARMACEU technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BASILEA PHARMACEU future price: according to them, PK5 price has a max estimate of 94.00 CHF and a min estimate of 52.00 CHF. Read a more detailed BASILEA PHARMACEU forecast: see what analysts think of BASILEA PHARMACEU and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BASILEA PHARMACEU EBITDA is ‪22.68 M‬ CHF, and current EBITDA margin is 14.39%. See more stats in BASILEA PHARMACEU financial statements.